Navigation Links
Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
Date:9/14/2007

HAMBURG, Germany, Sept. 14 /PRNewswire/ -- Indivumed announces today that a service agreement with Roche Diagnostics GmbH was signed. Within this agreement Indivumed will apply its automated immunohistochemistry service platform for analyzing various biomarkers and drug targets in the area of oncology. Indivumed will provide for this project a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples. The analysis of specific biomarkers and drug targets should enable Roche to efficiently develop novel targeted therapies for cancer.

Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Kensington, Maryland, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6500 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.


'/>"/>
SOURCE Indivumed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CDW buyer supports Berbee growth plans
2. Tech center supports energy-saving device for heat-treating plants
3. Inacom Supports Blackhawk Technology Mentor Program
4. Computer Card Supports Solo Doctor
5. Federal Funding Supports Small Business Innovation
6. Advantages of Roche Applied Science amplification products
7. Roche Diagnostics Corporation
8. Roche Diagnostics Corporation
9. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
10. Prodesse enters patent agreement with Roche
11. A prognosis for GE and Abbott Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):